- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07320157
The Effect of HPV Education Provided to Women on Their Knowledge Levels, HPV Screening, and Vaccination Uptake (HPV-Education)
"Women's HPV Education and Its Effects on Knowledge Levels, HPV Screening Behaviors, and HPV Vaccination Uptake: An Interventional Education Study"
Type of Study: This study was planned to be an observational study.
Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question[s] it aims to answer [is/are]:
H1: There is a difference in the mean Human Papillomavirus (HPV) Knowledge Scale score between the intervention group women who participated in Human Papillomavirus (HPV) education and the control group women.
H2: There is a difference between the intervention group women and the control group women in terms of their participation in HPV screening tests.
H2: There is a difference between the intervention group women and the control group women in terms of their HPV vaccination status.
Participants Participants will be assigned to a control and intervention group. Online training will be provided to the intervention group, and the results of the training will be reported.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ankara
-
Ankara, Ankara, Turkey (Türkiye), 06000
- UfUK UNIVERSITY
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Being female
- Women aged 18-35 years
- Ability to speak and understand Turkish at a level sufficient to communicate with the researcher
- Having the technical equipment necessary to participate in a video interview
- No diagnosis of HPV positivity
- Not having received the HPV vaccine
- Not having undergone HPV DNA/Pap smear testing in the past 5 years
- No diagnosis of cervical cancer
- Voluntary willingness to participate in the study
- No diagnosis of a psychiatric disorder
Exclusion Criteria:
- Being male
- Having severe physical or cognitive impairments that prevent completing the questionnaire
- Being under 18 years of age or over 35 years of age
- Inability to speak or understand Turkish
- Lack of technical equipment to participate in a video interview
- Having a diagnosis of HPV positivity
- Having received the HPV vaccine
- Having undergone HPV DNA/Pap smear testing in the past 5 years
- Having a diagnosis of cervical cancer
- Having a diagnosed psychiatric disorder
Not agreeing to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Online Education Intervention Group
An online training session will be scheduled for the intervention group.
The training will consist of two 40-minute session.
After the online training, the training materials will be shared with the group.
One week after the training, an informational brochure prepared on the topic will be sent to the intervention group via WhatsApp as a reminder, and any questions they may have will be answered.
Two weeks after delivering the brochure, the questionnaire/scale forms will be administered to both groups as the first follow-up.
Eight weeks after the first follow-up, the same forms will be administered again as the post-test.
The WhatsApp group will remain open and interaction will be allowed throughout the research period.
|
An online training session will be scheduled for the intervention group.
The training will consist of two 40-minute session.
After the online training, the training materials will be shared with the group.
One week after the training, an informational brochure prepared on the topic will be sent to the intervention group via WhatsApp as a reminder, and any questions they may have will be answered.
Two weeks after delivering the brochure, the questionnaire/scale forms will be administered to both groups as the first follow-up.
Eight weeks after the first follow-up, the same forms will be administered again as the post-test.
The WhatsApp group will remain open and interaction will be allowed throughout the research period.
No intervention will be applied to the control group.
Following the completion of the study, the brochure prepared on the topic will be sent to them via WhatsApp.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HPV Knowledge Score
Time Frame: Baseline (before intervention), 2 weeks after brochure delivery (first follow-up), and 8 weeks after the first follow-up (final follow-up)
|
Change in participants' HPV Knowledge Scale scores measured at baseline, first follow-up, and final follow-up.
The measure evaluates the effect of the online education and brochure intervention compared to the control group.
|
Baseline (before intervention), 2 weeks after brochure delivery (first follow-up), and 8 weeks after the first follow-up (final follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sustained HPV Knowledge Score (Knowledge Retention)
Time Frame: Knowledge retention will be assessed by comparing HPV Knowledge Scale scores between groups at the final follow-up. Higher scores indicate better long-term retention of information provided by the intervention.
|
Final follow-up (8 weeks after the first follow-up)
|
Knowledge retention will be assessed by comparing HPV Knowledge Scale scores between groups at the final follow-up. Higher scores indicate better long-term retention of information provided by the intervention.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Disease Attributes
- Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Tumor Virus Infections
- Pathological Conditions, Signs and Symptoms
- Papillomavirus Infections
Other Study ID Numbers
- E-81182178-605-56406
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.